Publishers Threaten OpenEvidence Margins

This is the core margin risk in OpenEvidence’s model, because the same publishers that make its answers more trustworthy can also become suppliers, rivals, and price setters at the same time. OpenEvidence gives clinicians free search and funds it with pharma and med device ads, while its credibility depends on licensed journal content from groups like NEJM and JAMA. If those publishers keep more AI value for themselves, OpenEvidence either pays more for content or earns less on each free user.1 2 3 4 5

• The business model is unusually sensitive to gross margin. OpenEvidence scaled from about $50M annualized revenue in June 2025 to $300M by July 2026 while staying ad funded, and later research describes roughly 90% gross margin. Higher publisher fees would hit the engine room of that model, not just a small cost line.1 2 3
• Publishers are not just selling archives, they are building their own AI surfaces. NEJM already has NEJM AI, and JAMA has expanded from JAMA+ AI into a dedicated JAMA AI journal launching in 2027. That means the content owners are moving closer to owning the clinician interface where discovery, trust, and sponsorship dollars can sit.4 5 6 7
• There is already a proven paid alternative to free, ads funded clinical search. UpToDate generated about $690M in 2025 revenue, with about 80% from institutional customers, and Wolters Kluwer commercially launched UpToDate Expert AI in October 2025. That gives health systems and publishers a template for trusted, subscription funded AI rather than ad supported access.2 6 8 9

The next step is a split market. OpenEvidence will keep pushing for scale through free clinician adoption, but publishers and incumbents will keep packaging their own trusted AI products for hospitals and enterprise buyers. As more of the medical knowledge stack becomes vertically integrated, free access becomes more expensive to sustain and more strategically important as a distribution wedge.2 4 6 8